Obesity
Conditions
Keywords
aerobic exercise, inflammatory markers
Brief summary
All study group patients performed aerobic exercise on a treadmill. approved by the American College of Sports Medicine. Both groups received a Mediterranean diet for 12 weeks tailored according to patients' caloric needs
Detailed description
All study group patients performed aerobic exercise on a treadmill approved by the American College of Sports Medicine. The program started with a warming-up phase through walking on a treadmill for 3-5 minutes at a slow speed. Then, 10-30 minutes of aerobic exercise training with moderate intensity (60-70% of maximum heart rate) and 10 minutes of cooling down with low speed and without inclination. Participants had 3 sessions/week for 3 months with close supervision of a physical therapist. Both groups received a Mediterranean diet for 12 weeks tailored to patients' caloric needs. They received instructions about the consumption of olive oil as added lipid, the consumption of nuts and olives as snacks, daily high consumption of vegetables, fruits, and whole grains, dairy products, bi-weekly consumption of legumes, bi-weekly consumption of fish, and monthly consumption of meat. The main beneficial components of the Mediterranean diet are monounsaturated fats such as oleic acid in olive oil, polyunsaturated fats such as omega-3, high amounts of flavonoids and antioxidants found in fruits and vegetables, and high amounts of fiber found mainly in foods with a low glycemic index
Interventions
All study group patients performed aerobic exercise on a treadmill. approved by the American College of Sports Medicine.
OTHERMediterranean diet
received a Mediterranean diet for 12 weeks tailored according to patients caloric needs
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Obese patients with BMI ranged from 30-39.9 kg/m 2. * Their age was from 35 to 45 years old. * Both genders. * Stable vital signs (blood pressure, respiratory rate and temperature) * Abdominal obesity measurements according to American heart association) * Obese patients have one or more abnormal value of lipids profile. * All patients with sedentary life style. * All patients had insulin resistance
Exclusion criteria
* Rheumatic, neurologic, cardiovascular, respiratory, renal, lung problems, malignant tumors, and undiagnosed fever, which would prevent them from participating in aerobic exercises. * Knee injury or knee surgery during the past six month or having a history of joint replacement or fracture or hereditary or acquired musculoskeletal disorders in lower limb. * Major vision disorders. * Drugs that would affect metabolism or balance. * Assistive devices for walking. * Pregnancy or breast feeding, and post-partum 12 months. * Abdominal or rectal anus surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Short Form Quality of Life Questionnaire (SF-36) | 12 weeks | To measure the health related quality of life (HRQOL)in obese patient. SF-36 (version 2.0) is a 36-item measure of generic HRQOL in which 35 questions are transformed into eight dimensions; physical functioning, role limitation to physical problems, bodily pain, general health, vitality, social functioning, role limitations to emotional problems, and mental health Scores on all eight dimensions range from zero to 100, where higher scores represent better HRQOL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory Measurements | 12 weeks | After a 12-hour overnight fast, venous blood samples were collected from each participant in all participants before and after 12 weeks of treatment to measure, LDL, HDL, total cholesterol, TG levels milligrams per deciliter (mg/dL) and fasting blood glucose (FBG) measured in mg/dL (milligrams per deciliter) ,C-reactive protein (CRP) measured in milligrams per liter (mg/L), and (ESR) was measured in millimeters per hour (mm/hr) and fasting serum insulin measured and reported in micro International Units per milliliter (uIU/mL) by commercially available kits. All samples were drawn between 8 and 10 a.m. for later analysis. |
| Blood Pressure Measures | 12 weeks | Systolic and diastolic blood pressures were measured for each participant before and after 12 weeks of treatment |
| body weight | 12 weeks | Body weight was measured for each participant in kilograms |
| height | 12 weeks | body height was measured for each participant in meters |
| waist and hip circumferences | 12 weeks | waist and hip circumferences were measured for each participant in centimeter |
Countries
Egypt
Outcome results
None listed